drugset / Trial / NCT00357604

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

NCT00357604

Phase 1 Completed 22 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to administer a combined oral contraceptive (ethinyl estradiol and norgestimate) with the HIV treatment of atazanavir and ritonavir to healthy females in order to assess if the concentrations of the oral contraceptive change. The safety of this treatment regimen will also be studied.

Timeline

Start
2006-07
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg Oral
Comparator Norgestimate Small molecule 0.18 mg Oral
Comparator Norgestimate Small molecule 0.215 mg Oral
Comparator Norgestimate Small molecule 0.25 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral
Comparator ethinyl estradiol Small molecule 25 ug Oral
Comparator ethinyl estradiol Small molecule 35 ug Oral